Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02823990
Title TG4010 and Nivolumab in Patients With Lung Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors University of California, Davis
Indications

lung non-small cell carcinoma

Therapies

MVA-MUC1-IL2 vaccine + Nivolumab

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST